Aescin: Difference between revisions
Content deleted Content added
m BR separated pieces interpreted as multiple names re-joined with WBR |
Cochrane update. No change in findings from 2006-2012 version, but I made the text more accurately reflect the findings. Removed primary RCT reference. This RCT was included in the systematic review, so the info still included. |
||
| Line 49: | Line 49: | ||
'''Aescin''' or '''escin''' is a mixture of [[saponin]]s with [[anti-inflammatory]], [[vasoconstrictor]] and [[vasoprotective]] effects found in ''[[Aesculus hippocastanum]]'' (the horse chestnut). Aescin is the main active compound in horse chestnut, and is responsible for most of its medicinal properties. |
'''Aescin''' or '''escin''' is a mixture of [[saponin]]s with [[anti-inflammatory]], [[vasoconstrictor]] and [[vasoprotective]] effects found in ''[[Aesculus hippocastanum]]'' (the horse chestnut). Aescin is the main active compound in horse chestnut, and is responsible for most of its medicinal properties. |
||
Evidence suggests that aescin is a safe and effective treatment for short-term treatment of [[chronic venous insufficiency]].<ref>{{Cite journal|last=Sirtori|first=C. R.|date=September 2001|title=Aescin: pharmacology, pharmacokinetics and therapeutic profile|url=https://www.ncbi.nlm.nih.gov/pubmed/11529685|journal=Pharmacological Research|volume=44|issue=3|pages=183–193|doi=10.1006/phrs.2001.0847|issn=1043-6618|pmid=11529685}}</ref><ref name=Pittler2012>{{Cite journal|last=Pittler|first=Max H.|last2=Ernst|first2=Edzard|date=2012-11-14|title=Horse chestnut seed extract for chronic venous insufficiency|url=https://www.ncbi.nlm.nih.gov/pubmed/23152216|journal=The Cochrane Database of Systematic Reviews|volume=11|pages=CD003230|doi=10.1002/14651858.CD003230.pub4|issn=1469-493X|pmid=23152216|via=}}</ref> Horse chestnut extract may be as effective and well-tolerated as the use of [[compression stockings]], however more high quality randomized controlled trials are required to confirm the effectiveness.<ref name=Pittler2012 /> |
|||
==Mechanism of action== |
==Mechanism of action== |
||
Revision as of 18:44, 18 July 2017
| |
| Names | |
|---|---|
| IUPAC name
(2S,3S,4S,5R,6R)-6-{[(3S,4S,4aR,6aR,6bS,8R,8aR,9R,10R,12aS,14aR,14bR)
| |
| Other names
Escin
| |
| Identifiers | |
| |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.027.164 |
| KEGG | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C55H86O24 | |
| Molar mass | 1131.269 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Aescin or escin is a mixture of saponins with anti-inflammatory, vasoconstrictor and vasoprotective effects found in Aesculus hippocastanum (the horse chestnut). Aescin is the main active compound in horse chestnut, and is responsible for most of its medicinal properties.
Evidence suggests that aescin is a safe and effective treatment for short-term treatment of chronic venous insufficiency.[1][2] Horse chestnut extract may be as effective and well-tolerated as the use of compression stockings, however more high quality randomized controlled trials are required to confirm the effectiveness.[2]
Mechanism of action
Aescin appears to produce effects through a wide range of mechanisms. It induces endothelial nitric oxide synthesis by making endothelial cells more permeable to calcium ions, and also induces release of prostaglandin F2α.[3][4][5] Other possible mechanisms include serotonin antagonism and histamine antagonism and reduced catabolism of tissue mucopolysaccharides.[3]
References
- ^ Sirtori, C. R. (September 2001). "Aescin: pharmacology, pharmacokinetics and therapeutic profile". Pharmacological Research. 44 (3): 183–193. doi:10.1006/phrs.2001.0847. ISSN 1043-6618. PMID 11529685.
- ^ a b Pittler, Max H.; Ernst, Edzard (2012-11-14). "Horse chestnut seed extract for chronic venous insufficiency". The Cochrane Database of Systematic Reviews. 11: CD003230. doi:10.1002/14651858.CD003230.pub4. ISSN 1469-493X. PMID 23152216.
- ^ a b Cite error: The named reference
Sirtoriwas invoked but never defined (see the help page). - ^ Carrasco OF, Vidrio H (July 2007). "Endothelium protectant and contractile effects of the antivaricose principle escin in rat aorta". Vascul. Pharmacol. 47 (1): 68–73. doi:10.1016/j.vph.2007.04.003. PMID 17512261.
- ^ Berti F, Omini C, Longiave D (August 1977). "The mode of action of aescin and the release of prostaglandins". Prostaglandins. 14 (2): 241–249. doi:10.1016/0090-6980(77)90169-1. PMID 897216.